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Abstract
Prostate cancer is one of themost prevalent cancers inmen. It is critical to identify and characterize oncogenes that drive the pathogenesis
of human prostate cancer. The current study builds upon previous research showing that a disintegrin and metallproteinase (ADAM)28 is
involved in the pathogenesis of numerous cancers. Our novel study used overexpression, pharmacological, andmolecular approaches to
investigate the biological function of ADAM28 in human prostate cancer cells, with a focus on cell proliferation andmigration. The results of
this study provide important insights into the role of metalloproteinases in human prostate cancer.
The expression of ADAM28 protein levels was assessed within human prostate tumors and normal adjacent tissue by
immunohistochemistry. Immunocytochemistry and western blotting were used to assess ADAM28 protein expression in human
prostate cancer cell lines. Functional assays were conducted to assess proliferation and migration in human prostate cancer cells in
which ADAM28 protein expression or activity had been altered by overexpression, pharmacological inhibition, or by siRNA gene
knockdown.
The membrane bound ADAM28 was increased in human tumor biopsies and prostate cancer cell lines. Pharmacological inhibition
of ADAM28 activity and/or knockdown of ADAM28 signiﬁcantly reduced proliferation and migration of human prostate cancer cells,
while overexpression of ADAM28 signiﬁcantly increased proliferation and migration.
ADAM28 is overexpressed in primary human prostate tumor biopsies, and it promotes human prostate cancer cell proliferation and
migration. This study supports the notion that inhibition of ADAM28 may be a potential novel therapeutic strategy for human prostate
cancer.
Abbreviations: ADAM = a disintegrin and metalloproteinase, CTGF = connective tissue growth factor, DHT =
dihydrotestosterone, IGF = insulin-like growth factor, IGFBP-3 = IGF binding protein-3, IL-6 = interleukin 6, RPMI = Roswell
Park Memorial Institute, VEGF = vascular endothelial growth factor, VWF = von Willebrand factor.
Keywords: ADAM28, metalloproteinase, migration, proliferation, prostate cancer
1. INTRODUCTION
Prostate cancer is the 2nd most common cancer in men, and the
5th most common cause of cancer-related deaths in men
worldwide.[1] The age-adjusted incidence of prostate cancer
has risen in line with an increase in the number of men being
tested and improvements in widespread diagnostic testing.[1]
Current therapies for prostate cancer such as androgen ablation
result in a reduction in symptoms seen in around 70% to 80% of
patients with advanced prostate cancer.[2] However, tumors can
relapse within 2 years and transform into an incurable androgen-
independent state,[3] and there are other disadvantages.[4,5] It is
therefore important to develop alternative treatment options,
which aim to reduce the proliferation and progression of prostate
cancer cells.
A disintegrin and metalloproteinases (ADAMs) are a gene
family of transmembrane and/or secreted proteins which regulate
cell phenotype via effects on cell adhesion, migration, proteolysis,
and signaling.[6–9] Numerous ADAM family members have
previously been linked with the malignant progression of human
prostate cancer. Fritzsche et al[10] report that ADAM8 expression
is associated with increased Gleason scores and positive node
status. ADAM9 expression is signiﬁcantly higher in prostate
cancer tissue than normal prostate tissue[11] and inhibition of
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ADAM9 expression in prostate cancer enhanced prostate cancer
sensitivity to chemotherapy and radiation.[12] Knockdown of
ADAM10 reduced proliferation of prostate cancer cells,
suggesting that ADAM10 may contribute to the progression of
prostate cancer by increasing proliferation.[13] McCulloch
et al[14] report that ADAM12 expression is signiﬁcantly higher
in prostate cancer tissues than normal prostate tissue. ADAM15
has been shown to contribute to the metastatic progression of
human prostate cancer through the binding of its disintegrin
domain to various integrins.[15] Finally, Xiao et al[16] demon-
strated that ADAM17 increased the invasive capacity of prostate
cancer cells by targeting matrix metalloproteinases (MMPs) 2
and 9. Interestingly, in contrast to other ADAM family members,
our team have elucidated that ADAM19 is a protective
biomarker in human prostate cancer.[17] Herein, we advance
current knowledge by focusing on the potential role of the
metalloproteinase ADAM28 in human prostate cancer to
determine if it could be a new target for intervention.
ADAM28 exists in 2 isoforms: a secreted soluble form
(ADAM28s) and a membrane bound form (ADAM28m).[18]
Both forms contain the metalloproteinase and disintegrin
domains, which function in proteolysis and cellular adhesion,
respectively. ADAM28 is expressed and synthesized in its
precursor form (zymogen form-proADAM28) by lymphocytes
and some cancer cells.[18] Studies have suggested that the
prodomain is required to maintain the latency of metal-
loproteinases,[19] and proADAM28 is activated by matrix
metalloproteinases-7 via the removal of its prodomain.[18] The
metalloprotease domain facilitates the degradation of several
substrates, including tumor necrosis factor-a[20] and others that
are discussed in more detail below. ADAM28’s disintegrin
domain is reported to bind the integrins a4b1, a4b7, and a9b1
on lymphocytes in an activation-dependent manner. The
leukocyte integrin interaction with ADAM28 proposes a
potential attachment and cleavage role for ADAM28 in
inﬂammation and immunity.[21,22]
ADAM28 cleaves substrates known to be involved in
metastasis including insulin-like growth factor (IGF) binding
protein-3 (IGFBP-3),[23] connective tissue growth factor
(CTGF),[24] and von Willebrand factor (VWF).[25] High levels
of the mitogen IGF-I and low levels of IGFBP-3 are associated
with a higher risk of prostate cancer in men.[26] Previous studies
have indicated that IGF-IR blockade reduces the invasive activity
of PC-3[27] and DU145[28] human prostate cancer cells. IGFBP-3
degradation by ADAM28 may play vital roles in carcinoma cell
proliferation and metastasis.[9]We have previously demonstrated
that ADAM28 cleaves VWF[25] and high levels of ADAM28
expression are implicated in the inactivation of proapoptotic
VWF. Studies from our team have also demonstrated that
overexpression of ADAM28 in human breast carcinoma cells
was positively associated with enhanced expression of both
vascular endothelial growth factor (VEGF) and CTGF.[24]
ADAM28 is suggested to be implicated in proliferation,
migration, and invasion in nonsmall cell lung cancer,[29] breast
cancer tissue,[23] bladder cancer,[30] head and neck cancer,[31] and
B-cell acute lymphoblastic leukemia.[32] Given that ADAM28 has
an oncogenic effect in other cancers and cleaves substrates with
known association with cancer metastases, these ﬁndings provide
a strong foundation for the investigation of ADAM28 in the
pathogenesis of human prostate cancer. Our study aimed to
determine the importance of ADAM28 in human prostate cancer,




Human prostate tumor biopsies (n=8) and paired adjacent
benign prostate tissue samples (n=8) were obtained from Dr
Ronald Cohen (Uropath, Perth, Western Australia). Tissue
samples were obtained with consent (institutional human ethics
application number EC 2008/118). Informed consent was
obtained from patients and a high standard of ethics was applied
in carrying out the investigations. Full face sections of prostate
cancer tissue were immunostained for ADAM28.
2.2. Immunohistochemistry
Tissue was ﬁxed in glutaraldehyde (2.5%) and parafﬁn
embedded. Sections were deparafﬁnized through xylene, rehy-
drated through graded alcohols to distilled water, and subjected
to antigen retrieval in EDTA pH 8.0 under pressure. After
blocking endogenous peroxide activity with hydrogen peroxide,
the mouse antihuman ADAM28 antibody (297-2F3)[23] was
applied at 1:500 for 60 minutes. A horse-radish peroxidase
labeled polymer conjugated with rabbit/mouse secondary anti-
bodies (DAKO envision+) was then incubated for 30 minutes.
Sections were visualized with diaminobenzidine (DAKO)
followed by a light counterstain with hematoxylin.
2.3. Cell culture
All cells were purchased from the American Type Culture
Collection (Manassas, VA). LNCaP and DU145 cells were
cultured in a 6 well cell bind plate (Costar) containing Roswell
Park Memorial Institute (RPMI)-1640 media (Sigma-Aldrich,
Steinheim, Germany) with 10% FCS and 2% penicillin/
streptomycin (Invitrogen, USA). They were maintained and
grown at 37 °C, in 95%O2/5% CO2. RWPE1 cells were cultured
in a 6 well cell bind plate containing Keratinocyte-serum-free
medium (Life Technologies) with 2% penicillin/streptomycin
(Invitrogen).
2.4. Determination of protein expression
Cell harvesting and western blots were conducted as previously
described.[20]
2.5. Antibodies
The primary antibodies used for western blot analysis were as
follows: anti-ADAM28 mouse monoclonal antibody (297-2F3)
speciﬁc to the ADAM28 metalloproteinase domain[29]; anti-
ADAM28 rabbit polyclonal antibody speciﬁc to the intra-
cytoplasmic domain (#ab39875, Abcam, Cambridge, USA);
mouse IgG isotype control (#sc-2025, Santa Cruz, Texas, USA);
mouse anti-b-actin antibody (Millenium), and rabbit anti-
prostate speciﬁc antigen polyclonal antibody (#A0562, Dako-
Cytomation). The secondary antibodies, antimouse IRDYE 800
and antimouse IRDYE 680 were purchased from Millennium.
2.6. Transfection of plasmids into cells
Transfection was conducted as previously described.[17] Trans-
fected cells were used for immunocytochemistry to evaluate
ADAM28 overexpression, proliferation, and migration studies.
The plasmid vectors utilized were pCMV Tag4A ADAM28 and
pCMV Tag4A empty vector.[33]
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2.7. Immunocytochemistry
Immunocytochemistry was conducted on transfected cells as
previously described.[17]
2.8. Enzyme-linked immunosorbent assay (ELISA)
Human IGF-I and interleukin-6 (IL-6) were measured in cell free
culture supernatants (collected from cells transfected for 48
hours) using commercially available ELISA kits as per manufac-
turer instructions (ELISAkit.com).
2.9. ADAM28 knockdown utilizing short-interfering RNA
(siRNA)
In all siRNA experiments, cells were seeded into 12 well cell
culture dishes, and transfections were conducted using X-
tremeGENE HP DNA transfection reagent (Roche). ADAM28
was knocked down using Silencer Select siRNA A28 siRNA 2
(#s21323, Applied Biosystems). The sequences are as follows:
Sense: CGACUAUUCUUGCAAGUG/Antisense: ACACUUG-
CAAGAAUAGUCG
siRNA (10nM) was added to 0.25105cells/mL suspended in
100mL of RPMI-1640 growth media and incubated for 48hours
(cells were free of streptomycin/penicillin for 4 hours). A Cy3
labeled double-stranded transfection control (scrambled siRNA;
IDT) was used at 10nM as a negative control.
2.10. Real time PCR analysis
Cells grown in 12 well plates were directly lysed with 200mL/well
of TRIzol Reagent (Invitrogen). RNA was isolated from the cells
in accordance to manufacturer’s instructions. RNA samples were
DNase treated using the RQ1 RNase-Free DNase (Cat# M6101,
Promega). DNase-treated RNA was mixed with a master mix
prepared from the TaqMan Reverse Transcription Reagents kit
(Applied Biosystems, Branchburg, NJ). The samples were then
reverse transcribed in the Gene Amp PCR system 9700
Thermocycler (Applied Biosystems).
To quantitate the relative expression of genes of interest from
extracted RNA samples, the cDNA samples were subjected
to real time PCR analysis. PCR reactions were composed of
cDNA sample, TaqMan master mix, DEPC-treated water,
and 20X Taqman assay from Life Technologies (HPRT
[Hs02800695_m1] or human ADAM28 [Hs00248020_m1]).
The cDNA samples were ampliﬁed using the Rotor Gene-2000
real-time PCR thermal cycler (Corbett Research). Real time PCR
data were analyzed using the comparative critical threshold (also
known as threshold cycle; CT) method.
2.11. Pharmacological inhibition of ADAM28
Cells were seeded into 2 separate treatments of either the dimethyl
sulfoxide (DMSO) or the ADAM28 inhibitor KB-R7785 (1–5m
M) diluted in DMSO.[23] Cells were then used for proliferation
and migration assays.
2.12. DHT treatment of prostate cancer cells
Prostate cancer cells were treated with 10nM dihydrotestoster-
one (DHT) for 24hours.
2.13. MTS assay
Cellswere suspended inRPMI-1640mediumcontaining 10%FCS
and 2% streptomycin/penicillin. After counting cells, they were
resuspended (0.125105cells/mL) and 100mLof cellswere added
to the center of the wells of a 96-well ﬂat bottom culture plate. The
medium was carefully aspirated on days 1, 3, 5, or 7 and replaced
with 100mL RPMI-1640 medium containing 10% FCS and 2%
streptomycin/penicillin containing 20mL of MTS assay reagent
(Promega). Proliferation was determined by the formation of a
colored formazanproduct. Plateswere readat 490nmusing aplate
reader. The Olympus ﬂuorescent microscope was used at each
required time point to image cells. The MTS assay result was
supported by cell count data in some experiments.
2.14. Transwell migration assays
Cell migration was assessed by an assay using transwells ﬁtted
with uncoated 8mm pore size polycarbonate membranes. Inserts
containing 100mL of FCS-free growth medium were placed into
wells of a 24 well plate possessing 10% FCS containing medium.
The transwell devices were left to equilibrate at 37 °C for 1 hour.
The FCS free growth medium was then replaced with new FCS-
free growth media containing LNCaP cells at a density of 0.25
105cells/mL and incubated at 37 °C for 1 and 3 days. Cells
attached to the bottom surface of the membrane at 2 and 3 days
post-seedingwere ﬁxed usingmethanol, followed by hematoxylin
staining. The membrane was then washed 3 times and cells
remaining on the upper surface of the membrane were removed
using a cotton swab. The bottom of the membrane was then
visualized using light microscopy at 200 magniﬁcation. Five
random high powered ﬁelds of view were captured and used to
analyze migration. Migrated cells were distinguished by their
dark blue opaque appearance.
2.15. Western blotting for endogenous IGFBP-3 cleavage
in DU145 cells
DU145 cells were starved in 0.1% serum-containing medium
overnight. The following day, cells were cultured in 0.1% serum
containing medium in the absence or presence of 1mM KB-
R7785 for 30minutes before adding IGF-I (100ng/mL). Cells
were then cultured for 24 hours. Serum-free conditioned cell
culture supernatants were concentrated using the Biomax 5k
Nmwl membrane (Millipore). The western blot for IGFBP-3
cleavage was conducted on concentrated cell culture medium
as previously described.[23] The rabbit anti-human IGFBP-3
antibody was a kind gift from Rob Baxter (Kolling Institute).
2.16. Statistical data analysis
Statistical analysis was carried out with the assistance of
Professor Max Bulsara (The University of Notre Dame) using
IBM SPSS statistics software. Nonparametric t tests (Mann–-
Whitney) were performed to compare mediums of sample
medium values when “n” was greater than 3. Statistical
signiﬁcance was determined if the probability of the null
hypothesis was less than 0.05 (P0.05). IBM SPSS statistics
was used to plot all graphs.
3. RESULTS
3.1. Human prostate carcinoma tissue displays elevated
ADAM28 expression
Human prostate tumor biopsies and paired adjacent benign
prostate tissue samples were immunostained for ADAM28
expression. The prostate tumor biopsies possessed Gleason
Rudnicka et al. Medicine (2016) 95:40 www.md-journal.com
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grades ranging from 7 to 8. First, prostate tumor samples
demonstrated negligible background immunoreactivity staining
when they were stained with non-immune mouse IgG1 (Fig. 1A).
However, we found that human prostate carcinoma samples have
increased ADAM28 expression (Fig. 1C, D) indicated by brown
staining when compared to normal human prostate tissue
(Fig. 1B). These data provided an incentive to explore the effects
of androgen on ADAM28 expression, which we were able to
evaluate in prostate cancer cells.
We also obtained normal and prostate tumor (Gleason score 9)
tissue for the assessment of ADAM28 protein expression by
western blotting. The active membrane-bound form of ADAM28
(55kDa) is elevated 2-fold in tumor tissue compared to normal
prostate tissue (Supplementary Fig. 1, http://links.lww.com/MD/
B318).
3.2. ADAM28 expression is increased in human prostate
cancer cells after dihydrotestosterone treatment
As androgen is a major driver in prostate cancer, we examined
whether ADAM28 expression is enhanced by exposure to
androgens, such as DHT. When androgen sensitive human
LNCaP prostate cancer cells were treated with andwithout DHT,
ADAM28 protein expression was increased greater than 3-fold in
the presence of DHT (Fig. 2). This was mirrored by an expected
increase in the expression of prostate speciﬁc antigen, the positive
Figure 1. Immunostaining of a disintegrin and metalloproteinase (ADAM)28 in human prostate cancer. (A) non-immune mouse IgG immunostaining of human
prostate tumor (Gleason grade 3+4=7), (B) ADAM28 immunostaining (brown) of benign prostate, (C) prostate tumor (Gleason grade 3+4=7), and (D) prostate
tumor (Gleason grade 4+4=8). All main photomicrographs are 100 magniﬁcation while insets are 300 magniﬁcation. Asterisk (panel B) indicates stroma and
arrow (panel C) indicates glandular hyperplasia.
Figure 2. ADAM28 protein expression is increased in the presence of DHT in androgen responsive human LNCaP prostate cancer cells. LNCaP cells were either
treated with DHT (10nM) or untreated (CON) for 24hours, in duplicate. (A) Western blot indicates that the presence of DHT increases the expression of both
ADAM28 and PSA when compared with the untreated controls. (B) Quantitation of ADAM28 expression. ADAM=a disintegrin and metalloproteinase, DHT=
dihydrotestosterone, PSA=prostate speciﬁc antigen.
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control, in the DHT treated samples compared to the controls.
Taken together, these data suggest that not only is ADAM28
expression associated with more poorly differentiated tumors, it
may be regulated by androgen in a feed-forward manner.
3.3. ADAM28 overexpression studies
We next evaluated the functional effects of transient over-
expression of ADAM28 in human prostate carcinoma cells
(DU145 and LNCaP). A plasmid encoding human ADAM28
cDNA was transiently transfected into the cells, resulting in
ADAM28 overexpression in both cell lines after 48hours.
Immunohistochemistry was performed on the cells using anti-
ADAM28 antibody (297-2F3). ADAM28 expression was
identiﬁed by strong brown cytoplasmic staining (Supplementary
Fig. 2, http://links.lww.com/MD/B318). The over-expressed
ADAM28 was detected as the active (55kDa) membrane bound
form (Supplementary Fig. 3, http://links.lww.com/MD/B318).
We next explored the effect of ADAM28 overexpression on
proliferation of DU145 and LNCaP human prostate cancer cell
lines compared to normal RWPE1 prostate epithelial cells. We
show by MTS cell proliferation assay that overexpression of
ADAM28 promotes proliferation of DU145 (Fig. 3A), LNCaP
(Fig. 3B), and RWPE1 cells (Fig. 3C). This result also conﬁrmed
that overexpression of ADAM28 stimulates proliferation of
human normal prostate epithelial and cancerous prostate cells.
3.4. Inhibition of ADAM28 reduces IGFBP-3 cleavage,
while overexpression of ADAM28 promotes IGF-I, but not
IL-6 release from human prostate carcinoma cells
Our previous studies highlight that the ADAM inhibitor KB-
R7785 is highly capable of inhibiting ADAM28-mediated
cleavage.[20] We now show that KB-R7785 may reduce
IGFBP-3 cleavage (22kDa product) in DU145 prostate cancer
cells (Fig. 4A).
Previous studies have shown that IGF-I and IL-6 inﬂuence the
invasiveness of prostate cancer cells, supporting the concept that
IGF-I and IL-6 are identiﬁable predictors of prostate cancer
prognosis. This is particularly relevant as ADAM28 is already
known to be a potential upstream mediator of IGF-I release from
cells.[23] An IGF-I ELISA performed on supernatant from DU145
cells that were transiently transfected with empty vector or
ADAM28 vector revealed that overexpression of ADAM28
signiﬁcantly increased IGF-I release (Fig. 4B). However, IL-6
ELISA data showed that ADAM28 overexpression does not
affect IL-6 release (Fig. 4C). Therefore, in a human prostate
cancer setting, the liberation of IGF-I appears to be regulated by
ADAM28.
3.5. Pharmacological inhibition of ADAM28 activity by
KB-R7785 attenuates proliferation of human prostate
carcinoma cells
Given that overexpression of ADAM28 can drive the prolifera-
tion of human prostate cancer carcinoma cells, we next
investigated the effect of inhibition of ADAM28 activity by
KB-R7785. Pharmacological inhibition of ADAM28 by KB-
R7785 signiﬁcantly reduced the proliferation of DU145 (Fig. 5A)
and LNCaP (Fig. 5B) human prostate cancer cells. These results
provide further conﬁrmation that ADAM28 plays a role in
promoting human prostate carcinoma cell proliferation.
Figure 3. Overexpression of ADAM28 in human prostate cancer cells and
normal prostate epithelial cells promotes proliferation. DU145 (A), LNCaP (B),
and RWPE1 (C) cells were either transiently transfected with empty vector
(pCMV-Tag4a) or an ADAM28 expressing vector (pCMV-Tag4a ADAM28).
Proliferation of cells was measured utilizing MTS reagent and read at 490nm
(∗P<0.02; ∗∗P<0.012; ∗∗∗P<0.001; ∗∗∗∗P=0.0001, Mann–Whitney) n=
6–16. Data are presented as a box and whisker plot. ADAM=a disintegrin and
metalloproteinase.
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3.6. siRNA knockdown of ADAM28 in human prostate
cancer cells
We also assessed the effect of knocking down ADAM28 using
siRNA. Fluorescentmicroscopyof LNCaPprostate carcinomacells
transfected with Cy3-labeled (red) scrambled siRNA conﬁrmed
high transfection efﬁciency (Supplementary Fig 4A and B, http://
links.lww.com/MD/B318). Real-time PCR for ADAM28 was
performed to conﬁrm ADAM28 siRNA-mediated knock down of
ADAM28 mRNA (Supplementary Fig 4C, http://links.lww.com/
MD/B318). Importantly, we observed a signiﬁcant decrease in the
proliferation of LNCaP cells treatedwithADAM28 siRNA relative
to Cy3-labeled scrambled siRNA (Fig. 5C). This result was also
repeated with a 2nd ADAM28 siRNA (data not shown).
3.7. Human prostate cancer cell migration is reduced
by ADAM28 inhibition
Finally, we examined the role of ADAM28 in prostate carcinoma
cell migration using Transwell chambers. We performed a
migration assay using LNCaP cells treated with KB-R7785 or
RWPE1 normal epithelial cells transfected with ADAM28 vector.
When ADAM28 activity was inhibited by KB-R7785 for 3 days,
migration of the LNCaP cells was signiﬁcantly reduced compared
to DMSO treated cells (Fig. 6A). Conversely, we found that
RWPE1 cells transfected with ADAM28 vector exhibited
signiﬁcantly increased migration compared to cells transfected
with empty vector after 2 days (Fig. 6B). Therefore, in addition to
regulating prostate cancer cell proliferation, ADAM28 may
mediate some aspects of prostate cancer cell migration.
4. DISCUSSION
This study highlights that ADAM28 is overexpressed in human
prostate cancer tissue biopsies. Furthermore, we demonstrated
that ADAM28 promotes proliferation and migration of
human prostate carcinoma cells. Interestingly, overexpression
of ADAM28 in human prostate carcinoma or normal prostate
epithelial cells enhanced cellular proliferation and migration,
while inhibition with an ADAM28 inhibitor or siRNA silencing
of ADAM28 reduced cellular proliferation and migration of
Figure 4. Inhibition of ADAM28 reduces IGFBP-3 cleavage, while overexpression of ADAM28 in DU145 human prostate cancer cells elevates IGF-1, but not IL-6
expression. (A) IGFBP-3 cleavage is inhibited by the ADAM inhibitor KB-R7785. (B) IGF-1 is signiﬁcantly increased when ADAM28 is overexpressed. (C) There is no
change in the expression of IL-6 when ADAM28 is over expressed; n=6–9 samples per treatment. Data are presented as mean±SEM. ∗P=0.03. ADAM=a
disintegrin and metalloproteinase, IGF= insulin-like growth factor, IGFBP-3= IGF binding protein-3, IL-6= interleukin 6, SEM=standard error of mean.
Figure 5. Proliferation of human prostate cancer cells is reduced when ADAM28 is pharmacologically inhibited by KB-R7785 or silenced by siRNA transfection. (A)
Proliferation (cells/mL) of DU145 cells treated with KB-R7785 (5mM) or DMSO (vehicle control) over a time course of 7 days, and (B) proliferation (optical density at
490nm) of LNCaP cells treated with KB-R7785 (1mM) or DMSO (vehicle control) over 7 days. ∗P<0.006, ∗∗P<0.007, (∗∗∗P<0.002; DMSO vs KB-R7785 for day
3 and 5); Mann–Whitney. Data are presented as a box and whisker plot (A and B), n=3–8. (C) Graph depicts proliferation (optical density) of LNCaP cells when
transiently transfected with ADAM28 siRNA or Cy3 scrambled control over 7 days. The proliferation of ADAM28ii siRNA transfected LNCaP prostate cancer cells
(dark gray) is signiﬁcantly reduced when compared to the Cy3 scrambled control (light gray) for all time-points. All P values<0.000004; n=7–8. Data are presented
as a box and whisker plot. ADAM=a disintegrin and metalloproteinase, DMSO=dimethyl sulfoxide, siRNA=short-interfering RNA, SEM=standard error of mean.
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human prostate carcinoma cells. Collectively, these ﬁndings
suggest that ADAM28may promote the pathogenesis of prostate
cancer via proliferation and migration. Thus, successful
therapeutic targeting of ADAM28 to inhibit its activity could
be a beneﬁcial approach in prostate cancer.
Our team previously elucidated that overexpression of
ADAM28 mediated breast carcinoma cell proliferation through
the liberation of IGF-I after proteolysis of IGFBP3.[23] In a
prostate cancer setting, IGF-I is a powerful mitogenic factor and
may promote the proliferation of prostate carcinoma cells.[34]
Based on these ﬁndings, the hypothesis that ADAM28may play a
key role in cell proliferation in human prostate carcinomas was
formulated. In our current study, we found that IGF-I liberation
is increased when ADAM28 is overexpressed. We propose that
this may be via ADAM28-mediated proteolysis of IGFBP3 on
prostate carcinoma cells as indicated in Fig. 4A.
The results in the present study indicated that inhibition of
ADAM28 by KB-R7785 signiﬁcantly reduced proliferation and
migration of human prostate carcinoma cells compared to
control cells. Although KB-R7785 has been shown to completely
inhibit ADAM28 activity,[18] it does have off-target effects on
ADAM12.[9,35] Interestingly, ADAM12 has been shown to be
essential for tumor development and progression in a mouse
model of prostate cancer.[36] Thus, in the studies using KB-
R7785, some of the functional effects observed could be due to
combined blockade of ADAM28 and ADAM12. Future studies
will delineate these effects by knocking down ADAM12
expression in prostate cancer or alternatively through the use
of an ADAM12 neutralizing antibody that would speciﬁcally
block the active site of ADAM12 in functional studies. Although
an important line of enquiry regards ADAM12, our data using
siRNA against ADAM28 and ADAM28 overexpression, vali-
dates ADAM28’s pathogenic role in prostate cancer.
Several studies have implicated the proinﬂammatory cytokine,
IL-6, in prostate cancer cell proliferation and migration.[37–40] In
our study, ADAM28 overexpression did not inﬂuence the level of
IL-6 secretion from human prostate cancer cells. Therefore, IL-6
is not a fundamental driver of ADAM28-mediated proliferation
and migration of human prostate cancer cells.
This initial study of ADAM28 and prostate cancer raises
several questions, including how ADAM28 is regulated in
prostate cancer and its mechanism of action. A recent study by
our team has veriﬁed that the oncogene Src induces ADAM28
expression.[41] The oncogene Src is involved in regulating cellular
proliferation, survival, migration, invasion, metastasis, and
angiogenesis.[41–45] In addition, we have shown that ADAM28
cleaves IGFBP3 to liberate IGF-I, which in part contributes to
carcinoma cell proliferation in breast cancer.[23] ADAM28 also
promotes VEGF165 bioavailability by digestion of the VEGF165/
CTGF complex.[24] Furthermore, anti-apoptosis of carcinoma
cells within blood vessels is due in part to ADAM28 degrading
VWF, enabling them to bypass VWF-induced apoptosis.[25]
Thus, these mechanisms could be operative in prostate cancer.
Numerous studies have highlighted a strong correlation
between the metabolic syndrome and prostate cancer stage.[46,47]
Interestingly, our group has demonstrated that ADAM28 is
signiﬁcantly elevated with the metabolic syndrome.[20] There is
mounting evidence that prostate cancers are more aggressive in
men with the metabolic syndrome than in men without.[46–51]
Interestingly, in our current clinical study, ADAM28 expression
in prostate biopsies appeared greater in patients with prostate
cancer (Fig. 1). It is possible, therefore, that expression of
ADAM28 may be greater in men with the metabolic syndrome
and prostate cancer.
In unpublished microarray data from a PhD dissertation,[52] it
was shown that DHT treatment of LNCaP cells resulted in a 20-
fold increase in ADAM28 mRNA expression. We now show that
DHT treatment of LNCaP cells increases ADAM28 protein
expression 3-fold compared to control cells (Fig. 2). Combined,
these results suggest that DHT promotes elevated ADAM28
protein expression in LNCaP cells at the transcriptional level.
In conclusion, we have shown for the ﬁrst time that ADAM28
is overexpressed in human prostate cancer and is involved in
driving the proliferation and migration of human prostate
carcinoma cells. Importantly, its activity can be inhibited readily
by a small molecule inhibitor, suggesting that it may be possible
to consider reduction of ADAM28 expression as a new
therapeutic strategy in prostate cancer. Further work with
validation in preclinical models will provide additional insight
into this exciting possibility.
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